Truist raised the firm’s price target on Editas Medicine to $20 from $15 and keeps a Buy rating on the shares. Safety and efficacy data from 11 dosed SCD and 6 dosed TDT patients look competitive to CASGEVY, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EDIT:
- Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
- Editas Medicine to hold a pharmaceutical update conference call
- Editas Medicine price target lowered to $10 from $12 at Barclays
- Options Volatility and Implied Earnings Moves Today, November 03, 2023
- Editas Medicine Announces Third Quarter 2023 Results and Business Updates
